Molecule to Market Penn Pharma offers end-to-end development from formulation to commercial production, presenting a attractive one-stop partner for clients seeking streamlined, accelerated timelines and reduced vendor management in drug development and supply.

Contained Potent Capabilities With facilities capable of handling highly potent molecules and a scalable range from 1 kg to 300 kg for non-potent and 1 kg to 120 kg for potent, Penn can win business from pharmas needing compliant containment and scalable manufacturing for early through late-stage programs.

Global Regulatory Expertise Licensed by MHRA, inspected by the FDA, and authorized for controlled drug import/storage by the UK Home Office, Penn’s regulatory and export experience supports multinational trials and market access, appealing to global sponsors seeking compliant supply chains.

Clinical to Commercial Experienced in clinical trial supply, formulation and analytical development, stability services, QA, and QP release, Penn can be a preferred partner for sponsors aiming to de-risk transitions from trial material to commercial-scale batches.

Strategic Capacity Position Recent capacity expansion delivering substantial on-site doses and a broad dosage form portfolio positions Penn to target mid-to-late stage programs and niche formulations, including unlicensed specials, for markets in Europe, the USA, South America, and Japan.